Successful treatment of cesarean scar pregnancy with transvaginal injection of absolute ethanol around the gestation sac via ultrasound

Fangfang Lu¹, Yuanming Liu² and Wenjun Tang*³

Abstract

Background: This study aims to evaluate the curative effect and complications in cesarean scar pregnancy (CSP) patients treated with a transvaginal injection of absolute ethanol (AE) around the gestation sac (GS) under ultrasound guidance.

Methods: This retrospective clinical investigation analyzed 26 CSP patients treated at the Affiliated Hospital of Guilin Medical University in Guilin, Guangxi, China, between January 1, 2018 and January 30, 2019. Outcomes and complications were analyzed following treatment with AE.

Results: Out of the entire group, 20 patients were successfully treated with a single AE injection, while the remaining six patients required two or three repeat injections. In 21 patients, the serum beta-human chorionic gonadotropin (β-hCG) level was reduced to > 50% 1 day after a single AE injection; in 19 patients, the serum β-hCG level was reduced to > 80% 4 days after a single AE injection. In all patients, the average time for serum β-hCG to reduce to normal levels (< 3.0 mIU/mL) was 36.50 ± 12.54 days. The overall cure rate of CSP by AE injection was 100%. Average length of hospitalization was 6.73 ± 3.66 days, with Patient 2 having the longest hospitalization at 17 days, and Patient 3 the shortest at 2 days. No adverse effects on hematopoietic, hepatic or renal function were observed in the short term.

Conclusion: The study demonstrated that transvaginal injection of AE around the gestation sac under ultrasound guidance had good clinical effects, fewer complications, and merit as a novel treatment for CSP. However, larger multicenter trials are needed to confirm the safety and effectiveness of this treatment.

Keywords: Absolute ethanol, Cesarean scar pregnancy, Transvaginal ultrasonography

Background

In recent years, the cesarean section (CS) rate has increased globally. With this rise, the incidence of cesarean scar pregnancy (CSP) has also increased, particularly in China. The reported morbidity of CSP ranges from 1/2216 to 1/1800 pregnancies, accounting for 4% of ectopic pregnancies [1, 2]. CSP, a long-term complication of CS, is defined as the implantation of the gestational sac at the uterine incision scar of the previous CS. If treatment of CSP is delayed, it may lead to several serious complications, including hemorrhage, uterine rupture, hysterectomy, and even loss of sequent fertility [3]. As such, standard management for CSP is timely termination of pregnancy.

Many treatments for CSP have been proposed. These include: uterine dilatation and curettage (D&C), hysteroscopy, laparoscopy, resection of CSP through a transvaginal approach, uterine artery embolization (UAE), high-intensity focused ultrasound, treatment by potassium chloride, treatment by systemic methotrexate (MTX), treatment by local MTX, and combined medical and surgical management [4–10]. The efficacy and safety of these CSP therapies have been assessed in many research studies. One systematic review of CSP treatment indicated the efficacy rate of

* Correspondence: tangwenjun56@qq.com
³Department of Clinical Laboratory, Affiliated Hospital of Guilin Medical University, Guilin 541000, Guangxi, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
systemic and/or local MTX was 62%, while surgical treatments were associated with a high success rate (≥96%) and low risk of hemorrhage (≤4%) [11]. Petersen et al. [10] systematically reviewed 2037 CSP patients and identified 14 different approaches, among which five were recommended for CSP treatment: transvaginal approach, hysteroscopy, laparoscopy, UAE in combination with D&C, and UAE in combination with D&C and hysteroscopy. Yamaguchi et al. [12] showed that transvaginal MTX injection cured eight CSP patients successfully. Another study reported the cure rate among 28 CSP patients at 100% via transvaginal ultrasound-guided embryo aspiration plus local MTX injection, an effective method with less complications or adverse effects [13]. However, the standard treatment protocol for CSP is not yet established.

Some data suggest absolute ethanol (AE) can also be used for ectopic pregnancy therapy. The first use of AE in the treatment of ectopic pregnancy was reported by Kajijima et al. [14] in 2006. Building on this study, Hisao et al. [15] recently reported a novel, less-invasive treatment for cervical pregnancy (CP) and CSP using local AE injection, which may be superior to MTX-based local injection therapy. It was shown that injection of AE into the lacunar space around the gestation sac rapidly decreased serum beta-human chorionic gonadotropin (β-hCG) [15]. The above research mainly studied the curative effect of AE injections on CP treatment. In our study, we focused on the treatment of CSP by transvaginal AE injection. The aim of the report was to evaluate the curative effect and complications among CSP patients treated with AE.

Methods
Approved by the hospital’s ethics committee, this retrospective clinical study analyzed 26 CSP patients treated at the Affiliated Hospital of Guilin Medical University in Guilin, Guangxi, China, between January 1, 2018 and January 30, 2019. Patient data were collected through archived medical records and all patients were clearly informed of their treatment modalities, as well as the risk of pregnancy preservation. All patients provided signed consent prior to the intervention. Clinical characteristics such as age, gravida para, size of gestation sac (GS), uterine scar thickness, and fetal heartbeat were reviewed. The change in serum β-hCG level and size of GS were dynamically measured after treatment. The change in white blood cells (WBC), hemoglobin (Hb), blood platelets (PLT), alanine transaminase (ALT), aspartate transaminase (AST), creatinine (Cr), and blood urea nitrogen (BUN) were also analyzed before and two months after treatment. Patients for whom follow-up was not possible were excluded from the study.

Diagnostic criteria of CSP
All patients became pregnant spontaneously. The diagnosis of CSP was based on standard sonographic [16, 17] findings, confirming the following: 1) No pregnancy sac in the uterine cavity or cervical canal; 2) The pregnancy sac was located in the scar of the previous cesarean section in the lower uterine segment; 3) Color doppler flow imaging showed high velocity and low obstruction of blood flow around the pregnancy sac; and 4) Continuity of the myometrium in the anterior uterine wall was interrupted, with the myometrium between the pregnancy sac and bladder wall thinner or even absent.

Transvaginal injection of AE around the gestation sac
Administered without anesthesia, AE (Anhydrous Ethanol Injection; XiLong Scientific, Shantou, Guangdong, China) was injected in all patients around the GS using a 20-G puncture needle under guidance of high-intensity imaging transvaginal ultrasonography (TVU) (HD11XE, Philips, USA). In all patients, initial AE dose was between 4.0 and 15.0 mL (mean 8.38 ± 2.65 mL), depending on GS size and serum β-hCG level. When the GS was larger or level of serum β-hCG higher, the patient required a higher AE dose. Total AE dosage was between 4.0 and 30 mL (mean 11.15 ± 6.37 mL).

Therapeutic evaluation
All patients were hospitalized for treatment. The effect of AE local injection was evaluated based on percentage decrease of serum β-hCG, calculated by dividing the initial level of serum β-hCG before the first AE injection. A second AE dose was given if the initial level of serum β-hCG was higher than 65000mIU/mL, or the serum β-hCG decrease was <50% one day after local injection, or <80% four days after local injection and the patient needed to be reassessed in subsequent days. For patients whose decline in β-hCG levels were not satisfactory after the second injection, additional doses were administered until the required decline in β-hCG was achieved. The serum β-hCG level was rechecked on the first day and fourth day after AE injection, followed by one week after AE injection, two or three days after one week, and at one month until the required level was reached (<3.0 mIU/mL). Meanwhile, the size of the GS was dynamically measured by TVU after AE injection until it completely disappeared.

Statistical analysis
SPSS 13.0 statistical software (IBM Corp., Armonk, NY, USA) was used to process all data. Descriptive statistics are given as standard deviation of the mean, frequency, and percentage. Paired sample t-tests were employed to assess the change of WBC, Hb, PLT, AST, ALT, Cr, and
BUN before and after AE injections. A value of P < 0.05 was defined as statistically significant.

Results
Table 1 shows the clinical features of the 26 CSP patients. Average patient age was 34.12 ± 5.39 years. Among the entire group, positive fetal heartbeat (FHB) was visible in 11 patients. In all patients, average uterine scar thickness was 4.07 ± 2.07 mm. A total of 20 patients were successfully treated with a single AE injection, with the remaining patients requiring two or three AE injections due to slowly decreasing serum β-hCG levels. Among the 26 patients, 18 received 4–10 mL of AE injection, five received 11–20 mL of AE injection, and three received 21–30 mL of AE injection. The overall cure rate of CSP by AE injection was 100%.

In four patients (2, 14, 15, 19), the initial level of serum β-hCG was higher than 65000 mIU/mL. Patients 2, 14, and 15 received second AE injections. Patient 19 received a third AE injection as the decline in β-hCG level was not obvious after the second injection (<30%). In subsequent observation, all of them reached the required β-hCG level. In 21 CSP patients, serum β-hCG level was reduced >50% one day after a single AE injection; this included Patients 2, 10 and 15, and Patient 13 who had the greatest decrease at 85.88%. Patient 10 received repeated injections due to serum β-hCG level reduction <80% four days after a single AE injection; subsequently, the β-hCG level gradually decreased to normal (patient 2 and 15 have shown above). In another five patients (1, 12, 14, 19, 21), the decrease of serum β-hCG was <50% and the smallest decline occurred in Patient 19 at 34.33%. Patient 1 received third injections due to the decline in β-hCG level not being obvious after the second injection (<30%) and finally decreased to an acceptable level. Patient 12 and 21 only received a single AE injection as their serum β-hCG level reduction was >80% 4 days after injection and the required β-hCG level was reached eventually (patients 14 and 19 as shown above). In 19 patients, the serum β-hCG level decreased >80% 4 days after a single AE injection, while decreased <80% in the other seven patients (1, 2, 10, 14, 15, 19 and 23). Patient 23 only received a single AE injection due to serum β-hCG level reduction >50% 1 day after injection, then decreasing to an acceptable level (patients 1, 2, 10, 14, 15 and 19 has shown above). In all patients, average time for serum β-hCG to reach normal (<3.0 mIU/mL) was 36.50 ± 12.54 days. Average length of hospitalization was 6.73 ± 3.66 days. Patient 2 had the longest hospitalization at 17 days, while Patient 3 had the shortest at 2 days.

Decline of serum β-hCG levels in all CSP patients is shown in Fig. 1. In the majority of patients, the time for serum β-hCG to drop to normal was 30 to 40 days. Patients 14, 15, 19, and 20 required the longest time (60 days) and Patient 4 the shortest (9 days). Figure 2 shows the change of TVU after AE injections for patients 3, 5, 7, and 11.

We further analyzed the change of WBC, Hb, PLT, ALT, AST, Cr, and BUN in all patients to evaluate short-term adverse effects of AE injection on hematopoietic function or hepatic and renal function. Table 2 shows values of Hb, WBC, and PLT before AE injection were 15.33 ± 10.38 U/L and 14.62 ± 5.51 U/L, respectively; the difference was not statistically significant compared with values at 2 months after AE injection (P > 0.05). Values of Cr and AST before AE injection were 15.33 ± 10.38 U/L and 14.62 ± 5.51 U/L, respectively; the difference was not statistically significant compared with values at 2 months after AE injection (P > 0.05). Values of Cr and BUN were also similar before and 2 months after AE injections, as shown in Table 2 (P > 0.05). One patient (Patient 2) required symptomatic treatment for persistent bleeding (>500 mL) and a moderate hematoma (Hb 84 g/L).

Discussion
CSP is a rare type of ectopic pregnancy, which has increased in recent years due to a rise in cesarean sections. As CSP may cause serious complications – including hemorrhage, uterine rupture, and hysterectomy – early diagnosis and timely treatment are critical. Affecting women of reproductive age, most patients tend to choose conservative treatment for pregnancy termination, desiring to preserve the uterus and retain reproductive function. In any case, the best treatment for CSP remains unclear.

Currently, many conservative strategies have been established, including systemic and/or local MTX, D&C, hysteroscopy, laparoscopy, transvaginal resection, UAE, high-intensity focused ultrasound, and combined treatment [10, 18–21]. Among these, systemic and local MTX are the most widely used forms of management for CSP due to their minimally invasive nature [22]. MTX is a dihydrofolate reductase inhibitor used in the treatment of autoimmune diseases, malignancy, and as an abortifacient [1]. In CSP treatment, the mechanism of action of MTX is the inhibition of embryonic growth by causing the destruction of trophoblast cells and reducing local tissue blood flow, subsequently leading to embryonic death. Once trophoblast cells are destroyed, β-hCG is released into the blood, ultimately leading to an initial increase in serum β-hCG levels. Response to MTX occurs over 5 to 7 days [15]. Previous studies on MTX treatments provided conflicting results, likely due to differences in study design, definition of response, and additional treatment. Some researchers have confirmed the effectiveness of MTX and recommend it as the first choice for conservative treatment [12, 23]. Conversely,
Table 1 The clinical features of 26 CSP patients treated with AE local injection

| Patients | Age range (year) | GP | GA | CS | Initial β-hCG mIU/mL | GS mm | uterine scar thickness mm | FHB | β-hCG at 1 day after AE injection mIU/mL | β-hCG decrease rate(%) at 1 day | β-hCG at 4 day after AE injection mIU/mL | β-hCG decrease rate(%) at 4 day | time for β-hCG reduced to normal day | Initial volume of AE injection mL | Total volume of AE injection mL | No. of AE injections | hospital stay (day) |
|----------|-----------------|----|----|----|----------------------|-------|--------------------------|-----|----------------------------------------|--------------------------------|------------------------------------------|---------------------------------|--------------------------------|-------------------------------|-------------------------------|------------------|------------------|
| 1        | 20–30           | G2P1 | 6w1d | 1   | 25,820                | 21 x 7 | 3.1                      | –   | 13,694                               | 46.96                             | 5820                                      | 77.46                          | 44                              | 5                             | 15                            | 3                | 14               |
| 2        | 41–50           | G3P2 | 6w4d | 2   | 84,663                | 28    | 3.0                      | +   | 41,344                               | 51.17                             | 17,938                                    | 78.81                          | 40                              | 9                             | 17                            | 2                | 17               |
| 3        | 41–50           | G3P2 | 5w4d | 1   | 2708                  | 9 x 6 | 2.9                      | –   | 611                                | 77.44                             | 173.8                                    | 93.58                          | 28                              | 4                             | 4                | 1                |
| 4        | 20–30           | G3P2 | 9w6d | 1   | 125.4                | 29 x 21 | 3.5                      | –   | 42.9                                | 65.79                             | 16.6                                     | 86.76                          | 9                              | 5                             | 5                | 1                |
| 5        | 31–40           | G4P1 | 8w0d | 1   | 59,196                | 29 x 17 | 5.0                      | +   | 18,625                               | 68.54                             | 4738                                      | 92.00                          | 40                              | 9                             | 9                | 1                |
| 6        | 31–40           | G5P2 | 7w0d | 2   | 63,052                | 37 x 10 | 2.9                      | –   | 26,222                               | 58.41                             | 4630                                      | 92.66                          | 40                              | 10                            | 10               | 1                |
| 7        | 31–40           | G5P1 | 8w2d | 1   | 17,165                | 17    | 6.0                      | +   | 6279                                | 63.42                             | 1631                                     | 90.50                          | 32                              | 6                             | 6                | 1                |
| 8        | 31–40           | G2P1 | 7w5d | 1   | 10,801                | 27 x 15 | 4.6                      | –   | 3307                                | 69.38                             | 425.9                                    | 96.06                          | 20                              | 5                             | 5                | 1                |
| 9        | 20–30           | G3P1 | 6w1d | 1   | 13,466                | 18 x 12 | 3.0                      | +   | 4890                                | 63.69                             | 1234                                     | 90.84                          | 43                              | 7                             | 7                | 1                |
| 10       | 20–30           | G4P3 | 5w6d | 3   | 42,061                | 19 x 13 | 2.0                      | +   | 20,432                               | 51.42                             | 12,112                                    | 71.20                          | 30                              | 6                             | 16               | 2                |
| 11       | 31–40           | G3P2 | 6w3d | 2   | 14,827                | 16    | 2.4                      | –   | 6149                                | 58.52                             | 2048                                      | 86.19                          | 36                              | 5                             | 5                | 1                |
| 12       | 31–40           | G6P2 | 8w0d | 2   | 36,177                | 18    | 3.0                      | –   | 20,785                               | 42.55                             | 5290                                      | 85.38                          | 34                              | 10                            | 10               | 1                |
| 13       | 31–40           | G2P1 | 6w5d | 1   | 22,038                | 17    | 3.9                      | –   | 3111                                | 85.88                             | 2090                                      | 90.52                          | 30                              | 15                            | 15               | 1                |
| 14       | 31–40           | G9P2 | 7w2d | 2   | 85,264                | 22 x 16 | 3.2                      | –   | 46,463                               | 45.51                             | 27,611                                    | 67.62                          | 60                             | 12                            | 24               | 2                |
| 15       | 31–40           | G3P1 | 9w4d | 1   | 65,103                | 39 x 20 | 3.4                      | +   | 32,139                               | 50.63                             | 19,500                                    | 70.05                          | 60                             | 10                            | 22               | 2                |
| 16       | 31–40           | G10P2 | 6w4d | 2   | 1203.4               | 23 x 14 | 1.4                      | –   | 491.4                               | 59.15                             | 190                                       | 84.21                          | 29                             | 6                             | 6                | 1                |
| 17       | 20–30           | G5P1 | 6w4d | 1   | 37,002                | 26 x 10 | 4.9                      | +   | 16,056                               | 55.61                             | 2310                                      | 93.76                          | 29                             | 10                            | 10               | 1                |
| 18       | 31–40           | G4P1 | 6w6d | 1   | 20,162                | 23 x 9  | 9.1                      | +   | 5012                                | 68.36                             | 931.5                                     | 95.38                          | 25                             | 8                             | 8                | 1                |
| 19       | 31–40           | G3P2 | 6w5d | 2   | 93,544                | 24 x 12 | 4.0                      | +   | 61,432                               | 34.33                             | 49,768                                   | 46.80                          | 60                             | 10                            | 30               | 3                |
| 20       | 20–30           | G4P2 | 7w3d | 2   | 56,255                | 32 x 20 | 5.9                      | +   | 26,486                               | 5292                              | 5270                                      | 90.63                          | 60                             | 10                            | 10               | 1                |
| 21       | 31–40           | G3P2 | 5w5d | 2   | 34,783                | 34 x 12 | 3.1                      | –   | 21,152                               | 39.19                             | 4312                                      | 87.60                          | 40                             | 8                             | 8                | 1                |
| Patients | Age range (year) | GP | GA | CS | Initial $\beta$-hCG (mIU/mL) | GS (mm) | uterine scar thickness (mm) | FHB | $\beta$-hCG at 1 day after AE injection (mIU/mL) | $\beta$-hCG decrease rate(%) at 1 day | $\beta$-hCG at 4 day after AE injection (mIU/mL) | $\beta$-hCG decrease rate(%) at 4 day | time for $\beta$-hCG reduced to normal day | Initial volume of AE injection (mL) | Total volume of AE injection (mL) | No. of AE injections | hospital stay (day) |
|----------|-----------------|----|----|----|-----------------|--------|--------------------------|-----|--------------------------|-----------------|--------------------------|-----------------|-------------------------|------------------|------------------|-----------------|-----------------|
| 22       | 20–30           | G3P1 | 7w5d | 1 | 46,520 | 31 × 17 | 3.0 | – | 22,870 | 50.84 | 2404 | 94.83 | 30 | 8 | 8 | 1 | 8 |
| 23       | 31–40           | G3P1 | 7w2d | 1 | 51,065 | 27 × 15 | 4.3 | – | 20,341 | 60.17 | 19,030 | 62.73 | 33 | 8 | 8 | 1 | 5 |
| 24       | 20–30           | G4P1 | 8w0d | 1 | 20,714 | 28 × 15 | 3.0 | + | 8216 | 60.34 | 927 | 95.52 | 31 | 10 | 10 | 1 | 6 |
| 25       | 41–50           | G5P1 | 7w0d | 1 | 3612 | 35 × 23 | 10.9 | – | 1222 | 66.17 | 432 | 88.04 | 31 | 12 | 12 | 1 | 7 |
| 26       | 31–40           | G2P1 | 7w1d | 1 | 19,316 | 16 | 4.2 | – | 5673 | 70.63 | 936 | 95.15 | 35 | 10 | 10 | 1 | 6 |

**Abbreviations**: AE absolute ethanol; GP gravid para; GA gestational age; CS cesarean section; $\beta$-hCG beta-human chorionic gonadotropin; GS gestational sac; FHB fetal heartbeat; CSP cesarean scar pregnancy.
another review showed that nearly a quarter of patients treated with systemic MTX needed additional treatment, and severe complications occurred in 13% of cases [10]. Repeated use of MTX may result in genital infection, leukopenia, hepatic dysfunction, and vaginal bleeding [13]. For reproductive age women, MTX also showed embryo toxicity and teratogenicity. If treated with MTX, CSP patients require restrictive contraception for at least 3 months before a subsequent pregnancy. Therefore, it is necessary to explore more effective and less complicated CSP treatment methods.

As early as 1973, researchers reported the use of AE for the induction of mid-trimester abortions [24]. Subsequently, in 2006, AE injection was first used for ectopic pregnancy therapy [14]. Recently, Hisao et al. [15] reported usage of transvaginal AE injection for cervical pregnancy and CSP, known as “trophoblast target therapy” (TTT). They focused on 16 cervical pregnancy patients and 3 CSP patients, showing a successful outcome of TTT with AE injections. In our study, we used local injection of AE guided by transvaginal sonography to treat 26 CSP patients with gestational ages (GA) ranging from 5 weeks to 9 weeks and 6 days. We saw clinical success, with a curative rate of 100%. Notably, 20 patients (76.92%) underwent only one injection and attained a satisfactory result, while the remaining 6 patients (23.08%) required repeat AE injections due to serum β-hCG levels decreasing slowly. In all patients, average time for serum β-hCG to reduce to normal was 36.50 ± 12.54 days. All patients saw clinical success, with a curative rate of 100%. Notably, 20 patients (76.92%) underwent only one injection and attained a satisfactory result, while the remaining 6 patients (23.08%) required repeat AE injections due to serum β-hCG levels decreasing slowly. In all patients, average time for serum β-hCG to reduce to normal was 36.50 ± 12.54 days. The time for serum β-hCG to reduce to normal for the majority of patients ranged from 30 to 40 days. A few patients required 60 days, possibly related to high initial β-hCG levels or different sensitivity to AE treatment. This indicated that AE local injection around the gestation sac was effective for early pregnancy between 5 weeks to 9 weeks and 6 days, and also had an obvious effect on cases with positive FHB. However, it takes a long time for β-hCG to normalize. The mechanism of action for AE is causing trophoblastic necrosis through coagulation and dehydration, thus inhibiting proliferation of trophoblast cells, rapidly causing a reduction in serum β-hCG levels after initial injection. Furthermore, ethanol was metabolized quickly and did not accumulate in the body, making low-dose AE non-toxic, allowing for repeated injection as needed. Among 26 patients, 69.23% received 4~10 mL of AE injection, 19.23% received 11~20 mL of AE injection, and 11.54% received 21~30 mL of AE injection. Furthermore, we compared WBC, Hb, PLT, AST, ALT, Cr, and BUN in all patients before and at 2 months after AE injections. Our results demonstrated that there were no significant differences in hematopoietic function, liver function, and renal function after treatment, indicating AE injection has no adverse effects on hematopoietic function or hepatic and renal function in the short term.

Massive hemorrhage is a common complication of CSP. In this study, only Patient 2 reported blood loss in excess of 500 mL, subsequently requiring treatment. None of the patients experienced devastating hemorrhage. Uterine rupture is another serious complication. Li et al. [13] showed that the risk of uterine rupture is increased in patients having the gestational sac near the serous layer of the uterus. With expectant management, other researchers showed that the incidence of uterine rupture in CSP patients with embryonic/fetal heart activity was 9.9%,
and hysterectomy was required in 15.2% during the first or second trimester, while uterine rupture rarely occurred in CSP patients without embryonic/fetal heart activity [25]. A recent review showed patients with multiple CS history and uterine scar thickness of < 2 mm were more likely to suffer from complications [26]. In all 26 patients, average cesarean scar thickness was 4.07 ± 2.07 mm. Patient 25 had the thickest uterine scar (10.90 mm) and Patient 16 had the thinnest uterine scar (1.40 mm). No uterine rupture was observed in any patient. It is notable that preserving the uterus is a major concern for both patients and their physicians, as it may influence menstruation and future fertility plans. In our study, all patients were treated successfully by AE local injection and did not require hysterectomy after treatment, thereby preserving their reproductive ability. Despite serious complications of CSP, some patients choose to continue pregnancy as reported in some research [25, 27]. Timor et al. [25] showed that a significant proportion of CSP patients who declined pregnancy termination progressed to the third trimester; thus, they considered termination of pregnancy as not the only therapeutic option offered to these patients. However, 39.2% of patients had severe bleeding, while uterine rupture occurred in 10.2% of patients, with

Table 2 Comparison of changes in routine blood index, liver function, and renal function before and after AE injection

|                    | Mean ± SD   | Two month after injection | P value |
|--------------------|-------------|---------------------------|---------|
|                    | Before injection | Two month after injection |         |
| Hb(g/L)            | 127.00 ± 11.27 | 125.86 ± 13.77            | 0.626   |
| WBC(x10^9/L)       | 8.61 ± 1.96   | 8.65 ± 1.70               | 0.901   |
| PLT(x10^9/L)       | 264.88 ± 58.80 | 269.38 ± 63.94           | 0.603   |
| ALT(U/L)           | 15.33 ± 10.38 | 14.93 ± 7.75              | 0.774   |
| AST(U/L)           | 14.62 ± 5.51  | 15.30 ± 5.85              | 0.409   |
| Cr (umol/L)        | 52.51 ± 8.44  | 50.23 ± 10.58             | 0.144   |
| BUN (mmol/L)       | 4.21 ± 1.80   | 4.53 ± 1.45               | 0.063   |

Fig. 2 Change in TVU after AE injection for patients 3, 5, 7, and 11

(a) Change in TVU for Patient 3.  
(b) Change in TVU for Patient 5.  
(c) Change in TVU for Patient 7.  
(d) Change in TVU for Patient 11.
most of them diagnosed as having abnormally invasive placenta at delivery. Therefore, in clinical practice, CSP patients should be fully aware of the risks of continuing pregnancy, enabling them to make informed decisions regarding termination. However, without follow-up studies, we cannot draw conclusions about long-term complications and reproductive function.

This report had some weaknesses, including its retrospective nature, and small number of CSP cases, possibly leaving the results open to bias. Due to the absence of comparison with other CSP treatments, we cannot fully assess if AE local injection is superior to other conservative treatments. Another limitation is that all patients in our study were not assessed with long-term follow-up, so other potential complications of AE and its effect on fertility are unknown.

Conclusions
Transvaginal injection of AE around the gestation sac under the guidance of ultrasound showed good clinical effects and can be used as a novel treatment for CSP. CSP patients treated with AE local injections can attempt spontaneous pregnancy or in vitro fertilization and embryo transfer (IVF-ET) treatment without contraception. However, this retrospective clinical investigation involved a small sample size and may have some limitations. Future studies with larger multi-center trials are needed to confirm the safety and effectiveness of this treatment.

Abbreviations
AE: Absolute ethanol; ALT: Alanine transaminase; AST: Aspartate transaminase; BUN: Blood urea nitrogen; CP: Cervical pregnancy; Cr: Creatinine; D&C: Dilation and curettage; FHB: Fetal heartbeat; GA: Gestational age; GP: Gravida para; Hb: Hemoglobin; MTX: Methotrexate; PLT: Blood platelets; TTT: Trophoblast target therapy; TVU: Transvaginal ultrasoundography; UAE: Uterine artery embolization; WBC: White blood cells; β-hCG: Beta-human chorionic gonadotropin

Acknowledgements
None.

Authors’ contributions
WJT contributed to the study design; FFL collected patients’ information, performed statistical analysis and drafted the manuscript; YML collected patients’ information. All authors have read and approved the manuscript.

Funding
None.

Availability of data and materials
We agree to allow the readers and journal to review our primary data if requested.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Affiliated Hospital of Guillin Medical University. All patients provided signed consent prior to the intervention. All patients consented to analysis of their medical records in our manuscript and we obtained the permission from the hospital.

Consent for publication
We have obtained consent for the publication of identifying images or other personal or clinical details from 26 patients.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Obstetrics and Gynecology, Affiliated Hospital of Guillin Medical University, Guillin 541000, Guangxi, People’s Republic of China.
2Department of Ultrasound, Affiliated Hospital of Guillin Medical University, Guillin 541000, Guangxi, People’s Republic of China. 3Department of Clinical Laboratory, Affiliated Hospital of Guillin Medical University, Guillin 541000, Guangxi, People’s Republic of China.

Received: 13 March 2019 Accepted: 20 August 2019
Published online: 27 August 2019

References
1. Rotas MA, Haberman S, Levger M. Cesarean scar ectopic pregnancies: etiology, diagnosis, and management. Obstet Gynecol. 2006;107(6):1373–81.
2. Mayron R, Svinsky R, Smorgick N, et al. Fertility performance and obstetric outcomes among women with previous cesarean scar pregnancy. J Ultrasound Med. 2011;30(9):1179–84.
3. Qian ZD, Weng Y, Du YJ, et al. Management of persistent cesarean scar pregnancy after curettage treatment failure. BMC Pregnancy Childbirth. 2017;17(1):208.
4. Dör UP, Palma-Dias R, Reidy KL, et al. Cesarean scar pregnancies: incidence and factors associated with conversion to surgery from medical management. J Minim Invasive Gynecol. 2019;26(5):919–27.
5. Liu S, Sun J, Cai B, et al. Management of Cesarean Scar Pregnancy Using Ultrasound-Guided Dilation and Curettage. J Minim Invasive Gynecol. 2016;23(5):707–11.
6. Zhuang YL, Huang LL. Uterine artery embolization compared with methotrexate for the management of pregnancy implanted within a cesarean scar. Am J Obstet Gynecol. 2009;201:152.e1–3.
7. Pintea L, Balint O, Secosan C, et al. Laparoscopic resection of cesarean scar ectopic pregnancy after unsuccessful systemic methotrexate treatment. J Minim Invasive Gynecol. 2019;26(3):399–400.
8. Yang H, Li F, Zhang P, et al. Treatment of caesarean section scar pregnancy with systemic administration of methotrexate: Pak J Pharm Sci. 2018;31(5):2287–90.
9. Czuczwar P, Stepniak A, Wiazniak A, et al. Successful treatment of spontaneous heterotopic cesarean scar pregnancy by local potassium chloride injection with preservation of the intrauterine pregnancy. Ginekol Pol. 2016;87(10):727.
10. Birch Petersen K, Hoffmann E, Riffbjerg Larsen C, et al. Cesarean scar pregnancy: a systematic review of treatment studies. Fertil Steril. 2016;105(4):958–67.
11. Maheux-Lacroix S, Li F, Bujold E, et al. Cesarean scar pregnancies: a systematic review of treatment options. J Minim Invasive Gynecol. 2017;24(6):915–25.
12. Yamauchi M, Honda R, Uchino K, et al. Transvaginal methotrexate injection for the treatment of cesarean scar pregnancy: efficacy and subsequent fecundity. J Minim Invasive Gynecol. 2014;21:877–83.
13. Li N, Zhu F, Fu S, et al. Transvaginal ultrasound-guided embryo aspiration plus local administration of low-dose methotrexate for cesarean scar pregnancy. Ultrasound Med Biol. 2012;38(2):209–13.
14. Kaijima H, Osada H, Kato K, et al. The efficacy and safety of managing ectopic pregnancies with transvaginal ultrasound-guided local injections of absolute ethanol. J Assist Reprod Genet. 2006;23:293–8.
15. Osada H, Teramoto S, Kaijima HA, et al. Novel treatment for cervical and cesarean section scar pregnancies by transvaginal injection of absolute ethanol to trophoblasts: efficacy in 19 cases. J Minim Invasive Gynecol. 2019;26(1):29–34.
16. Winder S, Reid S, Condous G. Ultrasound diagnosis of ectopic pregnancy (J. Australas. J Ultrasound Med. 2011;14:29–33.
17. Fylstra DL. Ectopic pregnancy within a cesarean scar: a review. Obstet Gynecol Surv. 2002;57:537–43.
18. Pędzieszewski P, Wędzak E, Panek W, et al. Cesarean scar pregnancy - a new challenge for obstetricians. J Ultrason. 2018;18(72):56–62.
19. Ohara Y, Wada S, Fukushi Y, et al. Laparoscopic Management of Cesarean Scar Pregnancy. J Minim Invasive Gynecol. 2019;26(5):798–9.
20. Grechukhina O, Deshmukh U, Fan L, et al. Cesarean scar pregnancy, incidence, and recurrence: five-year experience at a single tertiary care referral center [J]. Obstet Gynecol. 2018;132(5):1285–95.
21. Glenn TL, Bembry J, Findley AD, et al. Cesarean scar ectopic pregnancy: current management strategies. Obstet Gynecol Surv. 2018;73(5):293–302.
22. Uludag SZ, Kutuk MS, Ak M, et al. Comparison of systemic and local methotrexate treatments in cesarean scar pregnancies: time to change conventional treatment and follow-up protocols. Eur J Obstet Gynecol Reprod Biol. 2016;206:131–5.
23. Boza A, Boza B, Api M. Cesarean scar pregnancy managed with conservative treatment. Iran J Med Sci. 2016;41(5):450–5.
24. Gomel V, Carpenter CW. Induction of mid-trimester abortion with intrauterine alcohol. Obstet Gynecol. 1973;41:455–8.
25. Calì G, Timor-Tritsch IE, Palacios-Jaraquemada J, et al. Outcome of cesarean scar pregnancy managed expectantly: systematic review and meta-analysis [J]. Ultrasound Obstet Gynecol. 2018;51(2):169–75.
26. Giampaolino P, De Rosa N, Morra I, et al. Management of Cesarean Scar Pregnancy: A Single-Institution Retrospective Review. Biomed Res Int. 2018;2018:6486407.
27. Timor-Tritsch IE, Khatib N, Monteagudo A, et al. Cesarean scar pregnancies: experience of 60 cases. J Ultrasound Med. 2015;34(4):601–10.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.